Benitec Biopharma Limited (BNTC) is one of the best performing stocks in the health care sector for companies listed on the New York Stock Exchange or NASDAQ exchange shortly after the opening bell on September 23. Shares of BNTC have climbed 9.77% about 30 minutes into the session to $1.46 after closing the day prior at $1.33. It’s early, but the stock has traded as high as $1.46 and as low as $1.32 so far. Today’s quick advance has come with about 7,306 shares changing hands, compared to an average 30-day volume of 19,602 for Benitec Biopharma Limited. The price is currently below the 30-day volume weighted average price of $1.32 for BNTC.
The share appreciation gives the company a market capitalization of $9.74 million based upon 7.33 million shares outstanding. It also means that BNTC has a price-to-book ratio of 0.51:1 and a price-to-earnings ratio of :1.
In the past 52 weeks, shares of BNTC have traded as low as $1.2 and as high as $7.3. Technical traders will take note that at $1.46, shares of BNTC are trading below their 200-day MA at $2.23 and below their 50-day MA at $1.69. Technical analysts pay close attention to these key moving averages because they often serve as technical support and resistance levels and because a move through or holding above them is typically regarded as bullish.
Who is BNTC?
Benitec Biopharma Ltd is engaged developing treatments for chronic and life-threatening diseases to address unmet medical needs, based on its transformational technology, DNA-directed RNA interference (ddRNAi). The company’s 15 employees are led by CEO Peter French from the corporate headquarters at F6A/1-15 Barr Street.
For more information on BNTC and other companies trading on the major exchanges, as well as the over the counter markets, or to be considered for contributing content for our distribution network, visit FinancialPress.com today.
All data provided by QuoteMedia, with stock data accurate as of 9:30 AM ET. FinancialPress.com is not responsible for inaccuracies in third-party supplied information.
FinancialPress.com is a leading publisher of market and investment news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the financial markets and global economies. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts, which in turn delivers a variety of unique opportunities for industry partnerships, corporate communications, market exposure and investment. A complete disclaimer can be viewed here. If you like this article, you can read more at FinancialPress.com
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of FinancialPress.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://financialpress.com/legal-disclaimer/.